Hana Muhammed Abdulsalam, H. (2018). Matrix Metalloproteinase 7 in Rheumatoid Arthritis Patients with Interstitial Lung Disease. The Egyptian Journal of Hospital Medicine, 71(3), 2697-2700.
Howaida Elsayed Mansour, Sherin Mohamed Hosny, Nermeen Samy Khalel, Hana Muhammed Abdulsalam. "Matrix Metalloproteinase 7 in Rheumatoid Arthritis Patients with Interstitial Lung Disease". The Egyptian Journal of Hospital Medicine, 71, 3, 2018, 2697-2700.
Hana Muhammed Abdulsalam, H. (2018). 'Matrix Metalloproteinase 7 in Rheumatoid Arthritis Patients with Interstitial Lung Disease', The Egyptian Journal of Hospital Medicine, 71(3), pp. 2697-2700.
Hana Muhammed Abdulsalam, H. Matrix Metalloproteinase 7 in Rheumatoid Arthritis Patients with Interstitial Lung Disease. The Egyptian Journal of Hospital Medicine, 2018; 71(3): 2697-2700.
Matrix Metalloproteinase 7 in Rheumatoid Arthritis Patients with Interstitial Lung Disease
The study aim: The purpose of this study is to measure the matrix metalloproteinase 7 (MMP7) in rheumatoid arthritis (RA) patients with interstitial lung disease (ILD) and to assess for any correlation with RA-disease activity. Research design: A cross sectional study. Sample: a purposive sample included 40 rheumatoid arthritis patients from Ain Shams University Hospitals Inpatient Department of Rheumatology and Outpatient Clinic. The results revealed that serum (S) MMP7 was significantly higher among RA patients with interstitial lung disease than patients without. Conclusion: The study documented that S.MMP7 may be used as a screening test for detection of interstitial lung disease in patients with rheumatoid arthritis. The study recommended: Measurement of serum MMP7 level to RA patients may be used as screening test for detection of ILD